Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MetaboMARKER

Financiado

A metabolism based prognostic biomarker for prostate cancer

Prostate cancer (PC) is the most prevalent tumour type among men. The fraction of patients that exhibit disease recurrence can reach 15% and they face an uncertain future, since this type of tumour is prone to resist to subsequent... ver más

31/12/2018

ASOCIACION CENTRO...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ASOCIACION CENTRO DE INVESTIGACION COOPERATIV... Actividades de organizaciones profesionales asociacion

TRL 4-5 | 50K€

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100% 100%

2 Participantes

ASOCIACION CENTRO DE INVESTI...

150.00K€ | Lider

UNIVERSAL CLASS SOLUTIONS

Proyectos interesantes

JCI-2011-11435 Estudio de Biomarcadores en Cáncer de Mama. Factores Pronóst... 96K€ Cerrado

PTQ-08-03-08219 Identificación de marcadores de diagnóstico precoz de cáncer... 55K€ Cerrado

CNS2023-144975 Cáncer 200K€ Cerrado

RTC-2016-5674-1 Determinación de perfiles metabolómicos en el diagnóstico pr... 482K€ Cerrado

CPP2021-009002 Multimodal Biomarkers for Precise Management of Metastatic P... 156K€ Cerrado

NUEVAS TÉCNICAS AVANZADAS PARA EL DIAGNÓSTICO... NUEVAS TÉCNICAS AVANZADAS PARA EL DIAGNÓSTICO, PRONÓSTICO Y... 190K€ Rechazado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 19 meses Fecha Inicio: 2017-05-16
Fecha Fin: 2018-12-31

Líder del proyecto

ASOCIACION CENTRO DE INVESTIGACION COOPERATIV...

TRL 4-5 | 50K€

Presupuesto del proyecto 150K€

Descripción del proyecto Prostate cancer (PC) is the most prevalent tumour type among men. The fraction of patients that exhibit disease recurrence can reach 15% and they face an uncertain future, since this type of tumour is prone to resist to subsequent therapeutic strategies. Current guidelines for treatment of PC include prostatectomy or radiotherapy as first line therapy for localized disease, and chemical castration followed by chemotherapy for recurrent PC. The lack of capacity to identify therapy responders vs. escapers in PC is one of the sources for its important mortality. The challenge resides in providing clinicians with a robust and affordable biomarker that informs about the success of first line therapy in localised PC, and that allows them to employ more intensive therapeutic strategies in high-risk patients. The development of such prognostic tools is urgently needed, since western societies are facing profound changes in the major PC risk factors, including age and obesity. Last, but not least, the cost of treating PC will progressively impose strong pressure in the public health system. In addition, patients that fail first-line therapy can be enrolled in subsequent therapies for up to a decade, and given their advance age (PC predominantly presents in the sixth decade of life) they frequently present endangering and costly co-morbidities and secondary effects. MetaboMARKER, a novel biomarker developed in the framework of the ERC-StG-336343-CancerMetab and already protected under a European patent, is able to differentiate patients harbouring a PC that would progress and potentially metastasize, from those that exhibited a disease that would not likely be a risk to their lives. Thus, MetaboMARKER may contribute to more efficient diagnosis, improved treatments and better distribution of funds in disease management. The aim of the present PoC is to further develop the final biomarker for its commercialization and define the best exploitation strategy plan.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores